In the first quarter of 2016, Xenetic Biosciences, Inc. (NasdaqCM:XBIO) closed the transaction.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.505 RUB | +10.15% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 1.53Cr | |
+45.82% | 75TCr | |
+40.95% | 63TCr | |
-6.16% | 35TCr | |
+19.86% | 33TCr | |
+9.32% | 30TCr | |
+18.45% | 25TCr | |
+11.88% | 22TCr | |
-0.78% | 22TCr | |
+5.90% | 16TCr |
- Stock Market
- Equities
- LIFE Stock
- News Pharmsynthez
- Xenetic Biosciences, Inc. announced that it has received $3.5 million in funding from Public Joint-Stock Company Pharmsynthez